news
New drug targets for a rare kidney and liver disease
In a joint international study, researchers have collaborated to uncover how mutations in a single gene called PKHD1 lead to symptoms associated with a rare kidney and liver disease...
List view / Grid view
Liver disease
news
Scientists discover immune system blind spot in hepatic cirrhosis
20 July 2016 | By Victoria White, Digital Content Producer
The discovery could lead to new treatments for bacterial infections, a leading cause of death in hepatic cirrhosis, without the need for antibiotics...
article
Strategies for identifying predictive biomarkers of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD), a consequence of sedentary life styles and high fat diets, has an estimated prevalence of about 30% in western countries. It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity. Additionally, polymorphisms within genes such as PNPLA3, TM6SF2, APOC3, NCAN and PPP1R3B correlate…
news
Forbion invests in Akarna Therapeutics’ $15 Million Series B Financing
16 February 2016 | By Victoria White
Akarna has said it will use the funds to accelerate the development of its lead FXR agonist drug candidate...
news
JQ1 prevents and reverses liver fibrosis in mice
9 December 2015 | By Victoria White
The discovery, made by scientists from the Salk Institute, could help the millions of people worldwide affected by liver fibrosis and cirrhosis, caused by alcoholism and diseases like hepatitis...
news
Functional human hepatocytes grown in the lab
30 November 2015 | By Victoria White
This groundbreaking development could help advance a variety of liver-related research and applications...
news
Breakthrough in fighting liver disease
3 September 2015 | By Victoria White
The University of Brighton has announced it is sharing in a €5.9m EU grant to support the development of a new treatment for chronic liver disease...
news
MRC scientists regrow liver from liver stem cells
21 July 2015 | By Victoria White
Medical Research Council (MRC) scientists have repaired a damaged liver in a mouse by transplanting liver stem cells grown in the laboratory...
news
Protein from Vibrio vulnificus can inhibit tumour cell growth by cutting the protein Ras
9 June 2015 | By Victoria White
Scientists have discovered that a toxin secreted by Vibrio vulnificus has potential to prevent the growth of tumours by cutting the protein Ras...
news
Alnylam files Clinical Trial Application for ALN-AAT for the treatment of Alpha-1 Liver Disease
21 May 2015 | By Victoria White
Alnylam has filed a Clinical Trial Application to initiate a Phase 1/2 clinical trial with ALN-AAT for the treatment of alpha-1 liver disease...
article
The promise of induced pluripotent stem cells for liver disease, toxicology and drug discovery
We discuss the steps required for differentiating human pluripotent stem cells into hepatocyte-like cells, and how long this process takes and the quality control measures needed...
news
Partnering for Cure programme announces new winning projects designed to investigate novel ways to cure viral diseases
13 November 2014 | By Bristol-Myers Squibb
The Partnering for Cure faculty of experts announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV)...
news
The end of hepatitis C?
6 May 2014 | By Red Door Communications
New evidence published to coincide with the International Liver Meeting showing the potential for elimination of hepatitis C across 15 countries by 2030...
news
Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR12 rates of up to 90%
10 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir...
news
New data from Phase 3 attain study of Janssen’s once-daily simeprevir compared to telaprevir in treatment-experienced adult patients with genotype 1 chronic hepatitis C
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...
